Chemomab Therapeutics (CMMB) Amortization (2022 - 2025)

Chemomab Therapeutics (CMMB) has 4 years of Amortization data on file, last reported at $625.7 billion in Q4 2025.

• For the quarter ending Q4 2025, Amortization rose 65.9% year-over-year to $625.7 billion; the trailing twelve-month figure through Dec 2025 stood at $1002.8 billion (changed N/A YoY), and the FY2025 full-year result was $510.2 billion, up 42.11% from the prior year.
• Amortization for Q4 2025 stood at $625.7 billion, up from $377.1 billion in the prior quarter.
• Across five years, Amortization topped out at $625.7 billion in Q4 2025 and bottomed at -$1.1 million in Q3 2023.
• The 4-year median for Amortization is $188.6 billion (2022), against an average of $250.7 billion.
• The widest annual swing landed in 2023, when Amortization tumbled 140.39%; it then soared 65.9% in 2025.
• A 4-year view of Amortization shows it stood at $2.8 million in 2022, then sank by 140.39% to -$1.1 million in 2023, then soared by 33052880.02% to $377.1 billion in 2024, then jumped by 65.9% to $625.7 billion in 2025.
• The last three Amortization figures came in at $625.7 billion (Q4 2025), $377.1 billion (Q4 2024), and -$1.1 million (Q3 2023), per Business Quant data.

Peer Comparison